(Q37918304)

English

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy

scientific article published on 16 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

1 reference

Europe PubMed Central

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

chronic myeloid leukemia

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

P J Shami

1

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

M Deininger

2

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

publication date

16 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

214-224

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

https://scigraph.springernature.com/pub.10.1038/leu.2011.217

0 references

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

The biology of CML blast crisis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Treatment of chronic myeloid leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Clonal evolution in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

"I am older, not elderly," said the patient with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Second-generation BCR-ABL kinase inhibitors in CML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

PML targeting eradicates quiescent leukaemia-initiating cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

IFNalpha activates dormant haematopoietic stem cells in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

21 January 2018

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

7 January 2021

based on heuristic

inferred from DOI database lookup

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

7 January 2021

based on heuristic

inferred from DOI database lookup

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.217

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2011.217

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37918304&oldid=2117926909"